SMAD2 and melanoma: Consistent with our observations, Lo and Witte [48] identified intense nuclear immunohistochemical staining of P-SMAD2 in benign nevi, melanoma in situ, and primary invasive melanoma, suggesting that the tumor cell autonomous TGF-β pathway is hyperactivated in response to autocrine and/or paracrine ligand activity.